We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

PS-Omega3 Supplementation to Attention Deficit Hyperactivity Disorder (ADHD) Children (ADHD-3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00700323
Recruitment Status : Unknown
Verified June 2008 by Tel-Aviv Sourasky Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : June 18, 2008
Last Update Posted : June 18, 2008
Information provided by:
Tel-Aviv Sourasky Medical Center

June 17, 2008
June 18, 2008
June 18, 2008
July 2008
July 2009   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
PS-Omega3 Supplementation to Attention Deficit Hyperactivity Disorder (ADHD) Children
Phase 2b Study of PS-Omega3 Conjugate Supplementation to ADHD Diagnosed Children
To assess the effect of phosphatidylserine-omega-3 consumption on the immune system parameters in children suffering from attention and concentration deficits.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
  • Dietary Supplement: PS-Omega3 conjugate supplementation
  • Dietary Supplement: placebo
  • Active Comparator: 1
    Patients receiving active product
    Intervention: Dietary Supplement: PS-Omega3 conjugate supplementation
  • Placebo Comparator: 2
    Patients receiving placebo
    Intervention: Dietary Supplement: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
July 2009
July 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Parental written informed consent.
  2. Age: 13≥ years ≥8 (including).
  3. Gender: both male and female.
  4. TOVA computerized test score ≤-1.8 at baseline.
  5. Language: Subjects, parents, and teachers must be able to read, write and speak Hebrew.
  6. Normal weight and height according to Israeli standards.
  7. 21 days without any treatment for ADHD symptoms, whether medication or food supplement.

Exclusion Criteria:

  1. History or current diagnosis of any serious systemic (e.g., diabetes, hyper/hypothyroidism, etc.) or neurological condition (e.g., epilepsy, brain tumors, etc.)
  2. Pervasive developmental disorder or Non-Verbal Learning Disability
  3. Any evidence of psychotic disorders, suicidal risk, any current psychiatric co-morbidity that required psychiatric pharmacotherapy.
  4. History of allergic reactions or sensitivity to marine products (seafood), soy or corn as well as any illness, which may jeopardize the participants health or limit their successful trial completion.
  5. Having a sibling already included in the study.
Sexes Eligible for Study: All
8 Years to 13 Years   (Child)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Yoni Manor STUDY PROJECT MANAGER, Enzymotec Ltd.
Tel-Aviv Sourasky Medical Center
Principal Investigator: Nachum Vaisman, Prof' Tel-Aviv Sourasky Medical Center
Tel-Aviv Sourasky Medical Center
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP